Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: A prospective, randomized, clinical study

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 8, 2011, Pages

  Mandhaniya, Sushil ^a   Swaroop, Chetanya ^a   Thulkar, Sanjay ^a   Vishnubhatla, Sreenivas ^a   Kabra, Sushil K ^a   Xess, Immaculata ^a   Bakhshi, Sameer ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

acute leukemia; amphotericin B; antifungal Prophylaxis; aspergillosis; induction; invasive fungal infection; pediatric; voriconazole

Indexed keywords

AMPHOTERICIN B; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DIPHENHYDRAMINE; PARACETAMOL; PREDNISONE; VINCRISTINE; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INJECTION SITE REACTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MUCORMYCOSIS; NAUSEA; NEPHROTOXICITY; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RIGOR; SEIZURE; SYSTEMIC MYCOSIS; TREATMENT FAILURE; VASCULAR ACCESS; VISUAL DISORDER; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MYCOSES; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 80455174229     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182331bc7     Document Type: Article

References (56)

1. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000;110:273-284.
2. Bow EJ, Loewen R, Cheang MS, et al. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: The pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21:361-369.
3. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidiasis infection after marrow transplantation. J Infect Dis. 1991;164:731-740.
4. Bow EJ. Invasive fungal infection in patients receiving intensive cytotoxic therapy for cancer. Br J Haematol. 1998; 101:1-4.
5. Rinaldi MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis. 1991;13:493-495.
6. Jantunen E, Piilonen A, Volin L, et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant. 2000;25:867-871.
7. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996;100:171-178.
8. Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant. 1999;24:1195-1199.
9. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: A multivariate analysis of risk factors. J Clin Oncol. 1990;8:280-286.
10. Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol. 2005;27:135-140.
11. Hovi L, Saxen H, Saarinen-Pihkala UM, et al. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007;48:28-34.
12. Gozdasoglu S, Ertem M, Buyukkececi Z, et al. Fungal colonization and infection in children with acute leukemia and lymphoma during induction therapy. Med Pediatr Oncol. 1999;32:344-348.
13. Athanassiadou F, Tragiannidis A, Kourti M, et al. Invasive fungal infections in children with haematological malignancies. A 5-year study. Pediatr Hematol Oncol. 2006;23:163-166.
14. Ninane J. A multicentre study of fluconazole versus oral polyenes in prevention of fungal infection in children with haematological or oncological malignancies: Multicentre study Group. Eur J Clin Microbiol Infect Dis. 1994;13:330-337.
15. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs. 2003; 4:974-990.
16. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: A prospective, randomized, doubleblind study. J Infect Dis. 1995;171:1545-1552.
17. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl JMed. 1992; 326:845-851.
18. Bodey GP, Anaissie EJ, Elting LS, et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer. 1994;73:2099-06.
19. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: Result of a randomized placebo-controlled, doubleblind, multicenter trial. Ann Intern Med. 1993;118:495-03.
20. Kappe R, Osterziel KJ, Ruchel R, et al. Fluconazole in patients at risk from invasive aspergillosis. J Med Vet Mycol. 1993; 31:801-808.
21. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida Krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-1277.
22. Sugar AM. Fluconazole and itraconazole: Current status and prospects for antifungal therapy. Curr Clin Top Infect Dis. 1993;13:74-98.
23. Van Custem J. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. Chemotherapy. 1992;38(Suppl 1):3-11.
24. Bradford CR, Prentice AG, Warnock DW, et al. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother. 1991;28:555-560.
25. Persat F, Marzullo C, Guyotat D, et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. European Journal of cancer. 1992;28A:838-841.
26. Wollf SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant. 2000;25:853-859.
27. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
28. Cap J, Mojzesova A, Kayserova E, et al. Fluconazole in children: First experience with prophylaxis in pediatric patients with cancer. Chemotherapy. 1993;39:438-442.
29. Kaya Z, Gursel T, Kocak U, et al. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer. 2009;52:470-475.
30. Grigull L, Kuehlke O, Beilken A, et al. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: A pilot study for evaluation of safety and efficacy. Pediatr Transplant. 2007;11:261-266.
31. Simon A, Besuden M, Vezmar S, et al. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer. 2007;15:213-220.
32. Kusuki S, Hashii Y, Yoshida H, et al. Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer. 2009;53:605-609.
33. Uhlenbrock S, Zimmermann M, Fegeler H, et al. Liposomal amphotericinB for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: Interim analysis of a prospective study. Mycoses. 2001;44:455-463.
34. Roman E, Osunkwo I, Militano O, et al. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer. 2008;50:325-330.
35. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: A multivariate analysis of risk factors. J Clin Oncol. 1990;8:280-286.
36. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
37. Scott LJ, Simpson D. Voriconazole: A review of its use in the management of invasive fungal infections. Drugs. 2007;67: 269-298.
38. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am. 2005;52:895-915.
39. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Ped Inf Dis. 2002;21:240-248.
40. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol. 2009;27: 3398-3409.
41. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, doubleblind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111-5118.
42. Torres A, Serrano J, Rojas R, et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol. 2009. [Epub ahead of print].
43. Vehreschild JJ, Böhme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007;55:445-449.
44. Mattiuzzi GN, Cortes J, Alvarado G, et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011;19:19-26.
45. Tomas JF, Delgabo P, Garcia-Zueco JC, et al. Safety and Efficacy of Primary Prophylaxis with voriconazole in Adult Patients with Acute Leukemia. Blood. (abstract 4373) 2007;110.
46. Martin T, Sharma M, Damon L, et al. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2010;12:45-50.
47. Gergis U, Markey K, Greene J, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010;45:662-667.
48. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis. 2006;55:209-212.
49. Gene AW, Timothy JG, Mahsa S, et al. Comparable efficacy and safty with voriconazole or posaconazole as primary antifungal prophylaxis in acute myeloid leukemia (AML) patients receiving induction chemotherapy. ASH. (abstract 2059) 2009.
50. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286-e1294.
51. Bates DW, Yu DT. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today. 01, 2003;39:8.
52. Tomaszewski K, Purkins L, : Visual effects with voriconazole. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001; (Abstract 639).
53. Ally R, Schurmann D, Kreisel W, et al. A randomized, doubleblind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33: 1447-1454.
54. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
55. Marty EM, Cosimi LA, Baden LR. Breakthrough zygomycosis after Med voriconazole treatment in recipients of hematopoietic stem cell transplants. N Engl J. 2004;350:950-952.
56. Shima H, Mihari M, Osumi T, et al. Differences in trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Can. 2010;54:1050-1052.